Literature DB >> 15184430

Multifocal detection of multidrug-resistant Pseudomonas aeruginosa producing the PER-1 extended-spectrum beta-lactamase in Northern Italy.

Laura Pagani1, Elisabetta Mantengoli, Roberta Migliavacca, Elisabetta Nucleo, Simona Pollini, Melissa Spalla, Rossana Daturi, Egidio Romero, Gian Maria Rossolini.   

Abstract

Forty-four nonreplicate clinical isolates of Pseudomonas aeruginosa that were resistant to extended-spectrum cephalosporins (ceftazidime and cefepime) and aztreonam, that putatively produced an acquired extended- spectrum beta-lactamase (ESBL), according to the results of a double-disk synergy test, and that had been involved in nosocomial outbreaks were obtained from six different hospitals in northern Italy and screened for the presence of bla(PER) ESBL determinants. Twenty isolates, associated with nine independent outbreaks that occurred in five hospitals in the Milan area and its surroundings during 1995-2000, were found to carry an acquired bla(PER-1) gene. PER-1 producers representative of the nine outbreaks exhibited a multidrug resistance (MDR) phenotype, including resistance to extended-spectrum cephalosporins, aztreonam, meropenem, aminoglycosides, and in most cases, imipenem and ciprofloxacin. An analysis of macrorestriction profiles of their genomic DNAs by pulsed-field gel electrophoresis revealed an overall clonal diversity of the PER-1 producers, although interhospital clonal spread was also observed. The bla(PER-1) gene was not transferable and appeared to be chromosomally located. An analysis of the EcoRI and EcoRV restriction fragment length polymorphisms of the bla(PER-1) locus revealed identical patterns for all isolates, and the characterization of a 1.9-kb region containing bla(PER-1) revealed a conserved structure in representatives of the various clonal lineages. The present findings indicate that MDR P. aeruginosa clones producing the PER-1 ESBL are endemic to this area of northern Italy, where they have been circulating since the mid-1990s and have been associated with several nosocomial outbreaks.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15184430      PMCID: PMC427849          DOI: 10.1128/JCM.42.6.2523-2529.2004

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  24 in total

1.  Outbreak of infections caused by Pseudomonas aeruginosa producing VIM-1 carbapenemase in Greece.

Authors:  A Tsakris; S Pournaras; N Woodford; M F Palepou; G S Babini; J Douboyas; D M Livermore
Journal:  J Clin Microbiol       Date:  2000-03       Impact factor: 5.948

Review 2.  Prescribing guidelines for severe Pseudomonas infections.

Authors:  Helen Giamarellou
Journal:  J Antimicrob Chemother       Date:  2002-02       Impact factor: 5.790

3.  Emerging extended-spectrum beta-lactamases in Proteus mirabilis.

Authors:  Laura Pagani; Roberta Migliavacca; Lucia Pallecchi; Cecilia Matti; Ernesto Giacobone; Gianfranco Amicosante; Egidio Romero; Gian Maria Rossolini
Journal:  J Clin Microbiol       Date:  2002-04       Impact factor: 5.948

Review 4.  Emerging carbapenemases in Gram-negative aerobes.

Authors:  P Nordmann; L Poirel
Journal:  Clin Microbiol Infect       Date:  2002-06       Impact factor: 8.067

5.  Clinical importance of extended-spectrum beta-lactamase (PER-1-type)-producing Acinetobacter spp. and Pseudomonas aeruginosa strains.

Authors:  Haluk Vahaboglu; Figen Coskunkan; Ozlem Tansel; Recep Ozturk; Nursu Sahin; Iftahar Koksal; Bekir Kocazeybek; Muserref Tatman-Otkun; Hakan Leblebicioglu; Mehmet Ali Ozinel; Halis Akalin; Sesin Kocagoz; Volkan Korten
Journal:  J Med Microbiol       Date:  2001-07       Impact factor: 2.472

6.  Characterization of Pseudomonas aeruginosa isolates: occurrence rates, antimicrobial susceptibility patterns, and molecular typing in the global SENTRY Antimicrobial Surveillance Program, 1997-1999.

Authors:  A C Gales; R N Jones; J Turnidge; R Rennie; R Ramphal
Journal:  Clin Infect Dis       Date:  2001-05-15       Impact factor: 9.079

7.  Dynamics of a nosocomial outbreak of multidrug-resistant Pseudomonas aeruginosa producing the PER-1 extended-spectrum beta-lactamase.

Authors:  F Luzzaro; E Mantengoli; M Perilli; G Lombardi; V Orlandi; A Orsatti; G Amicosante; G M Rossolini; A Toniolo
Journal:  J Clin Microbiol       Date:  2001-05       Impact factor: 5.948

8.  Multiple mechanisms of antimicrobial resistance in Pseudomonas aeruginosa: our worst nightmare?

Authors:  David M Livermore
Journal:  Clin Infect Dis       Date:  2002-01-25       Impact factor: 9.079

9.  Hospital outbreak of multiple clones of Pseudomonas aeruginosa carrying the unrelated metallo-beta-lactamase gene variants blaVIM-2 and blaVIM-4.

Authors:  S Pournaras; M Maniati; E Petinaki; L S Tzouvelekis; A Tsakris; N J Legakis; A N Maniatis
Journal:  J Antimicrob Chemother       Date:  2003-04-25       Impact factor: 5.790

10.  An outbreak of multidrug-resistant Pseudomonas aeruginosa associated with increased risk of patient death in an intensive care unit.

Authors:  Geir Bukholm; Tone Tannaes; Anne Britt Bye Kjelsberg; Nils Smith-Erichsen
Journal:  Infect Control Hosp Epidemiol       Date:  2002-08       Impact factor: 3.254

View more
  29 in total

1.  Detection of extended-spectrum beta-lactamases in clinical isolates of Pseudomonas aeruginosa.

Authors:  Xiaofei Jiang; Zhe Zhang; Min Li; Danqiu Zhou; Feiyi Ruan; Yuan Lu
Journal:  Antimicrob Agents Chemother       Date:  2006-09       Impact factor: 5.191

2.  Novel TEM-type extended-spectrum beta-lactamase, TEM-134, in a Citrobacter koseri clinical isolate.

Authors:  Mariagrazia Perilli; Claudia Mugnaioli; Francesco Luzzaro; Marianna Fiore; Stefania Stefani; Gian Maria Rossolini; Gianfranco Amicosante
Journal:  Antimicrob Agents Chemother       Date:  2005-04       Impact factor: 5.191

3.  Biochemical characterization of PER-2 and genetic environment of blaPER-2.

Authors:  Pablo Power; José Di Conza; María Margarita Rodríguez; Bárbara Ghiglione; Juan A Ayala; José María Casellas; Marcela Radice; Gabriel Gutkind
Journal:  Antimicrob Agents Chemother       Date:  2007-04-16       Impact factor: 5.191

4.  Prevalence of multidrug resistant and extended spectrum beta-lactamase producing Pseudomonas aeruginosa in a tertiary care hospital.

Authors:  Sibhghatulla Shaikh; Jamale Fatima; Shazi Shakil; Syed Mohd Danish Rizvi; Mohammad Amjad Kamal
Journal:  Saudi J Biol Sci       Date:  2014-06-07       Impact factor: 4.219

5.  BEL-2, an extended-spectrum beta-lactamase with increased activity toward expanded-spectrum cephalosporins in Pseudomonas aeruginosa.

Authors:  Laurent Poirel; Jean-Denis Docquier; Filomena De Luca; Annemie Verlinde; Louis Ide; Gian Maria Rossolini; Patrice Nordmann
Journal:  Antimicrob Agents Chemother       Date:  2009-11-02       Impact factor: 5.191

6.  Tn5393d, a complex Tn5393 derivative carrying the PER-1 extended-spectrum beta-lactamase gene and other resistance determinants.

Authors:  Elisabetta Mantengoli; Gian Maria Rossolini
Journal:  Antimicrob Agents Chemother       Date:  2005-08       Impact factor: 5.191

7.  Characterization of the extended-spectrum β-lactamases and determination of the virulence factors of uropathogenic Escherichia coli strains isolated from children.

Authors:  Branka Bedenić; Jasmina Vraneš; Sabine Hofmann-Thiel; Marija Tonkić; Anita Novak; Viljemka Bučević-Popovic; Harald Hoffmann
Journal:  Wien Klin Wochenschr       Date:  2012-08-16       Impact factor: 1.704

8.  Interspecies dissemination of the bla gene encoding PER-1 extended-spectrum β-lactamase.

Authors:  Il Kwon Bae; Sook Jin Jang; Juwon Kim; Seok Hoon Jeong; Byungkyu Cho; Kyungwon Lee
Journal:  Antimicrob Agents Chemother       Date:  2010-12-13       Impact factor: 5.191

9.  Isolation and genomic characterization of a pathogenic Providencia rettgeri strain G0519 in turtle Trachemys scripta.

Authors:  Minghao Ye; Xiucai Hu; Aijun Lü; Jingfeng Sun; Chengxun Chen
Journal:  Antonie Van Leeuwenhoek       Date:  2020-09-20       Impact factor: 2.271

10.  Emergence of multidrug-resistant Proteus mirabilis in a long-term care facility in Croatia.

Authors:  Branka Bedenić; Nataša Firis; Vesna Elveđi-Gašparović; Marija Krilanović; Krešimir Matanović; Iva Štimac; Josefa Luxner; Jasmina Vraneš; Tomislav Meštrović; Gernot Zarfel; Andrea Grisold
Journal:  Wien Klin Wochenschr       Date:  2016-05-25       Impact factor: 1.704

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.